Scholar Rock (NASDAQ:SRRK) CEO David Hallal Sells 57,450 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) CEO David Hallal sold 57,450 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $2,453,115.00. Following the sale, the chief executive officer directly owned 1,541,645 shares in the company, valued at $65,828,241.50. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Scholar Rock Price Performance

Scholar Rock stock traded up $0.95 during mid-day trading on Thursday, reaching $46.53. 988,383 shares of the company’s stock traded hands, compared to its average volume of 911,044. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $48.28. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock has a 50 day moving average of $42.02 and a two-hundred day moving average of $36.87. The company has a market cap of $4.75 billion, a price-to-earnings ratio of -14.77 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the company posted ($0.66) EPS. Equities analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of analyst reports. Truist Financial lowered their price target on Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, October 20th. Citigroup initiated coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price for the company. UBS Group started coverage on Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Barclays lifted their price target on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Finally, Wolfe Research started coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective on the stock. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and an average target price of $50.14.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in shares of Scholar Rock by 609.3% during the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the last quarter. Millennium Management LLC lifted its stake in Scholar Rock by 37.4% in the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after buying an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after buying an additional 34,594 shares in the last quarter. Finally, Intech Investment Management LLC raised its holdings in shares of Scholar Rock by 60.9% during the first quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock valued at $1,826,000 after acquiring an additional 21,483 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).